Regulus Therapeutics Inc (RGLS)
2.13
-0.08
(-3.62%)
USD |
NASDAQ |
Apr 19, 16:00
2.13
0.00 (0.00%)
After-Hours: 20:00
Regulus Therapeutics Cash from Operations (TTM): -26.77M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -26.77M |
September 30, 2023 | -26.90M |
June 30, 2023 | -27.35M |
March 31, 2023 | -27.26M |
December 31, 2022 | -25.53M |
September 30, 2022 | -27.10M |
June 30, 2022 | -25.93M |
March 31, 2022 | -24.80M |
December 31, 2021 | -24.13M |
September 30, 2021 | -13.11M |
June 30, 2021 | -12.04M |
March 31, 2021 | -12.24M |
December 31, 2020 | -12.54M |
September 30, 2020 | -20.70M |
June 30, 2020 | -20.92M |
March 31, 2020 | -21.39M |
December 31, 2019 | -19.82M |
September 30, 2019 | -18.86M |
June 30, 2019 | -25.59M |
March 31, 2019 | -32.10M |
December 31, 2018 | -43.27M |
September 30, 2018 | -50.36M |
June 30, 2018 | -50.58M |
Date | Value |
---|---|
March 31, 2018 | -55.70M |
December 31, 2017 | -58.77M |
September 30, 2017 | -62.78M |
June 30, 2017 | -66.61M |
March 31, 2017 | -66.63M |
December 31, 2016 | -56.88M |
September 30, 2016 | -58.82M |
June 30, 2016 | -55.12M |
March 31, 2016 | -47.54M |
December 31, 2015 | -49.86M |
September 30, 2015 | -44.47M |
June 30, 2015 | -41.47M |
March 31, 2015 | -41.73M |
December 31, 2014 | -39.51M |
September 30, 2014 | -37.17M |
June 30, 2014 | -32.79M |
March 31, 2014 | -30.20M |
December 31, 2013 | -28.33M |
September 30, 2013 | -18.16M |
June 30, 2013 | -13.51M |
March 31, 2013 | -10.75M |
December 31, 2012 | -8.721M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-27.35M
Minimum
Jun 2023
-12.04M
Maximum
Jun 2021
-21.74M
Average
-24.13M
Median
Dec 2021
Cash from Operations (TTM) Benchmarks
ACADIA Pharmaceuticals Inc | 16.70M |
ADMA Biologics Inc | 8.80M |
FibroGen Inc | -315.02M |
Protara Therapeutics Inc | -37.56M |
Amylyx Pharmaceuticals Inc | 11.92M |